Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRTK

Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

Paratek Pharmaceuticals logo

About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)

Key Stats

Today's Range
$2.23
$2.23
50-Day Range
$2.17
$2.23
52-Week Range
$1.29
$3.65
Volume
N/A
Average Volume
724,253 shs
Market Capitalization
$127.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Paratek Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
1st Percentile Overall Score

PRTK MarketRank™: 

Paratek Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat, and ranked 941st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Paratek Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for PRTK.
  • Dividend Yield

    Paratek Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Paratek Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for PRTK.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Paratek Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Paratek Pharmaceuticals' insider trading history.
Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRTK Stock News Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
See More Headlines

PRTK Stock Analysis - Frequently Asked Questions

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analyst estimates of $22.98 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Paratek Pharmaceuticals investors own include Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), Verastem (VSTM), Citius Pharmaceuticals (CTXR), SCYNEXIS (SCYX) and Aurinia Pharmaceuticals (AUPH).

Company Calendar

Last Earnings
11/08/2021
Today
10/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CIK
1178711
Employees
268
Year Founded
1996

Profitability

EPS (Trailing Twelve Months)
($1.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.57 million
Net Margins
-35.44%
Pretax Margin
-35.35%
Return on Equity
N/A
Return on Assets
-40.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.52
Quick Ratio
0.46

Sales & Book Value

Annual Sales
$160.27 million
Price / Sales
0.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.08) per share
Price / Book
-0.72

Miscellaneous

Outstanding Shares
57,320,000
Free Float
52,736,000
Market Cap
$127.82 million
Optionable
Optionable
Beta
1.70

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:PRTK) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners